Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:NTLA NYSE:NVS NASDAQ:VYGR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNTLAIntellia Therapeutics$13.02-8.4%$14.40$7.95▼$28.25$1.99B1.775.73 million shs7.47 million shsNVSNovartis$153.35-0.5%$150.96$112.34▼$170.46$293.95B0.452.05 million shs1.18 million shsVYGRVoyager Therapeutics$3.24-5.8%$3.70$2.88▼$5.55$207.85M1.27668,176 shs1.00 million shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNTLAIntellia Therapeutics-8.44%-27.02%+7.51%-11.91%+12.92%NVSNovartis-0.46%-1.32%+0.21%-0.04%+26.81%VYGRVoyager Therapeutics-5.81%-10.50%-7.43%-18.39%-7.16%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNTLAIntellia Therapeutics$13.02-8.4%$14.40$7.95▼$28.25$1.99B1.775.73 million shs7.47 million shsNVSNovartis$153.35-0.5%$150.96$112.34▼$170.46$293.95B0.452.05 million shs1.18 million shsVYGRVoyager Therapeutics$3.24-5.8%$3.70$2.88▼$5.55$207.85M1.27668,176 shs1.00 million shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNTLAIntellia Therapeutics-8.44%-27.02%+7.51%-11.91%+12.92%NVSNovartis-0.46%-1.32%+0.21%-0.04%+26.81%VYGRVoyager Therapeutics-5.81%-10.50%-7.43%-18.39%-7.16%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNTLAIntellia Therapeutics 2.35Hold$20.6758.79% UpsideNVSNovartis 2.31Hold$141.20-7.92% DownsideVYGRVoyager Therapeutics 2.75Moderate Buy$16.50409.26% UpsideCurrent Analyst Ratings BreakdownLatest VYGR, NVS, and NTLA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/10/2026NTLAIntellia Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$12.00 ➝ $17.006/16/2026NTLAIntellia Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$49.006/15/2026NTLAIntellia Therapeutics New Street ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$25.006/15/2026NTLAIntellia Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.006/15/2026NTLAIntellia Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform6/15/2026NTLAIntellia Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$12.006/15/2026NTLAIntellia Therapeutics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$30.005/26/2026VYGRVoyager Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/13/2026NTLAIntellia Therapeutics Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Perform$13.00 ➝ $17.005/13/2026NTLAIntellia Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$30.00 ➝ $25.005/12/2026NTLAIntellia Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$58.00 ➝ $49.00(Data available from 7/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNTLAIntellia Therapeutics$67.67M26.88N/AN/A$5.80 per share2.24NVSNovartis$54.53B5.37$10.69 per share14.34$22.04 per share6.96VYGRVoyager Therapeutics$40.37M4.85N/AN/A$3.53 per share0.92Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNTLAIntellia Therapeutics-$412.69M-$3.54N/AN/AN/A-597.04%-57.47%-46.24%8/6/2026 (Estimated)NVSNovartis$13.98B$6.9821.9715.762.6524.87%38.82%15.16%7/21/2026 (Estimated)VYGRVoyager Therapeutics-$119.72M-$1.97N/AN/AN/A-319.61%-55.97%-43.12%8/5/2026 (Estimated)Latest VYGR, NVS, and NTLA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2026Q2 2026NTLAIntellia Therapeutics-$0.80N/AN/AN/A$12.98 millionN/A8/5/2026Q2 2026VYGRVoyager Therapeutics-$0.55N/AN/AN/A$4.56 millionN/A7/21/2026Q2 2026NVSNovartis$2.17N/AN/AN/A$14.16 billionN/A5/11/2026Q1 2026NTLAIntellia Therapeutics-$0.92-$0.81+$0.11-$0.81$13.81 million$15.05 million5/7/2026Q1 2026VYGRVoyager Therapeutics-$0.54-$0.47+$0.07-$0.47$8.79 million$1.19 million4/27/2026Q1 2026NVSNovartis$2.11$1.99-$0.12$1.65$13.44 billion$13.52 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthNTLAIntellia TherapeuticsN/AN/AN/AN/AN/ANVSNovartis$3.082.01%+5.28%44.13%N/AVYGRVoyager TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNTLAIntellia TherapeuticsN/A6.106.10NVSNovartis0.960.850.65VYGRVoyager TherapeuticsN/A8.428.42Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNTLAIntellia Therapeutics88.77%NVSNovartis13.12%VYGRVoyager Therapeutics48.03%Insider OwnershipCompanyInsider OwnershipNTLAIntellia Therapeutics3.50%NVSNovartis0.01%VYGRVoyager Therapeutics12.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNTLAIntellia Therapeutics600139.72 million134.83 millionOptionableNVSNovartis75,2671.91 billion1.91 billionOptionableVYGRVoyager Therapeutics10060.42 million52.75 millionOptionableVYGR, NVS, and NTLA HeadlinesRecent News About These CompaniesVoyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026July 13 at 3:27 PM | markets.businessinsider.comVoyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer's Disease Expected H2 2026July 13 at 8:01 AM | globenewswire.comCramer to a 23-Year-Old: Buy It, but It Might Take a ‘Lifetime’ to Make MoneyJuly 2, 2026 | aol.comACramer to a 23-Year-Old: Buy It, but It Might Take a ‘Lifetime' to Make MoneyJuly 2, 2026 | 247wallst.comVoyager Therapeutics (VYGR) is Amongst the Best Stocks Under $10, With More Than 50% UpsideJune 30, 2026 | finance.yahoo.comVoyager’s Tau-Targeted Gene Therapy VY1706 for Alzheimer’s Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026June 29, 2026 | markets.businessinsider.comVoyager's Tau-Targeted Gene Therapy VY1706 for Alzheimer's Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026June 29, 2026 | globenewswire.comVoyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid ConferenceJune 11, 2026 | globenewswire.comVoyager Therapeutics Highlights 2026 CNS Pipeline and StrategyJune 10, 2026 | theglobeandmail.comVoyager Therapeutics Expands Authorized Shares After Stockholder VoteJune 10, 2026 | tipranks.comHere's Why We're A Bit Worried About Voyager Therapeutics' (NASDAQ:VYGR) Cash Burn SituationJune 9, 2026 | finance.yahoo.comVoyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer’s DiseaseJune 1, 2026 | markets.businessinsider.comVoyager Therapeutics IND Cleared for Alzheimer’s Gene TherapyJune 1, 2026 | tipranks.comVoyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer's DiseaseJune 1, 2026 | globenewswire.comWhat Voyager Therapeutics Inc (VYGR) Has Gained on Its Therapy ProgramsMay 20, 2026 | finance.yahoo.comVoyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer’s Disease Expected H2 2026May 13, 2026 | markets.businessinsider.comVoyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer's Disease Expected H2 2026May 13, 2026 | globenewswire.comVoyager Therapeutics (VYGR) Reports Q1 Loss, Misses Revenue EstimatesMay 7, 2026 | zacks.comVoyager Reports First Quarter 2026 Financial and Operating ResultsMay 7, 2026 | globenewswire.comH.C. Wainwright Reaffirms Their Buy Rating on Voyager Therapeutics (VYGR)May 1, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMission Control: Floating In SpaceX's Record-Breaking OrbitBy Jeffrey Neal Johnson | June 15, 2026Gravity Check: Houston, SpaceX Has a Valuation ProblemBy Jeffrey Neal Johnson | June 16, 20265 Tech Stocks to Buy on the July PullbackBy Thomas Hughes | June 29, 2026The Oil Trade May Not Be Over: 3 Energy Stocks to WatchBy Thomas Hughes | June 21, 20263 European Stocks to Carry Investors Through the Back Half of 2026By Chris Markoch | July 1, 2026VYGR, NVS, and NTLA Company DescriptionsIntellia Therapeutics NASDAQ:NTLA$13.02 -1.20 (-8.44%) Closing price 07/13/2026 04:00 PM EasternExtended Trading$13.36 +0.34 (+2.64%) As of 08:31 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Novartis NYSE:NVS$153.35 -0.70 (-0.45%) Closing price 07/13/2026 03:59 PM EasternExtended Trading$152.55 -0.80 (-0.52%) As of 08:32 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.Voyager Therapeutics NASDAQ:VYGR$3.24 -0.20 (-5.81%) Closing price 07/13/2026 04:00 PM EasternExtended Trading$3.39 +0.15 (+4.75%) As of 08:30 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The SK Hynix IPO and 2027’s AI Memory Squeeze Why Welltower's Growth Story Might Outrun Its Rich Valuation Why Micron Is Doubling Down While the HBM Shortage Persists AMD's 5C Deal Positions It as a Direct NVIDIA Rival China's Helium Ban Could Reshape the AI Supply Chain The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions Analysts See Major Upside for These 5 Stocks One Short- and One Long-Term ETF for Quantum Computing Bulls Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
